Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether jaw opening exercises alone changes maximal mouth opening (interincisal distance) compared with ultrasound plus jaw opening exercises (very low certainty).
1 finding from 1 review
Persistence of the anal fissure · patients with fissure in ano
Open showed no clear difference in persistence of the anal fissure compared with closed partial lateral internal sphincterotomy (high certainty).
1 finding from 1 review
Minor incontinence to flatus · patients with fissure in ano
Open showed no clear difference in minor incontinence to flatus compared with closed partial lateral internal sphincterotomy (moderate certainty).
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether surgery plus Heister jaw opener changes maximal mouth opening (interincisal distance) compared with surgery plus wooden tongue depressors (very low certainty).
2 findings from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) showed no clear difference in maximal mouth opening (interincisal distance) compared with placebo or no active treatment (low certainty).
3 findings from 1 review
MD -1.41 [-5.74, 2.92]
1 study · 90 participants
Low
MD 3.11 [0.46, 5.77]
2 studies · 520 participants
Low
MD 8.83 [8.22, 9.45]
3 studies · 620 participants
Moderate
Difficulty in mouth opening (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) led to lower difficulty in mouth opening (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review
Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Adverse effects: Clinically important general adverse effect (no data) · schizophrenia
1 finding from 1 review
Death: Suicide and natural causes (no data) · schizophrenia
1 finding from 1 review
Length of hospital stay · schizophrenia
1 finding from 1 review
Mental state: Average endpoint general mental state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with zuclopenthixol depot (very low certainty).
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in adverse effects: 1. Extrapyramidal side effects (TESS) compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Sedation/tranquillisation: Not sedated ‐ at four hours · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Global state: 1. Requiring supplementary medication ‐ antipsychotics · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Global state: 2. Requiring 3 or more injections ‐ over 7 days · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Mental state: 1. Not markedly improved (BPRS, < 60% decrease in BPRS score) · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in mental state: 1. Not markedly improved (BPRS, < 60% decrease in BPRS… compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review